<DOC>
	<DOC>NCT00784680</DOC>
	<brief_summary>To compare Quality of Life between the ARIMIDEX group, the NOLVADEX group and the ARIMIDEX plus NOLVADEX combination group during the first two years of treatment. (a) To compare the difference in Quality of Life between the ARIMIDEX group and the NOLVADEX group (b) To compare Quality of Life in the ARIMIDEX plus NOLVADEX combination group with the NOLVADEX group for non-inferiority; if non inferiority is concluded, the difference in QOL between these two groups will be assessed.</brief_summary>
	<brief_title>ATAC - Quality of Life Sub-Protocol</brief_title>
	<detailed_description />
	<mesh_term>Anastrozole</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Eligible for entry into the main ATAC trial 1033IL/0029 Completion of a baseline questionnaire Excluded from entry into the main ATAC trial (1033IL/0029) If, in the investigators opinion, the patient would be unable to comply with this subprotocol due to psychiatric or literacy reasons</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
</DOC>